Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid

International Journal of Molecular Sciences

Volumn 18, Issue 8, 2017, Pages

  Kozela, Ewa ^a,b   Juknat, Ana ^a,b   Vogel, Zvi ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Astrocyte; Cannabidiol; Cannabinoid; Neurodegeneration; Neuroinflammation

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; AMYLOID BETA PROTEIN; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; EXCITATORY AMINO ACID TRANSPORTER; FATTY ACID AMIDASE; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NABIXIMOLS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN S100B; REACTIVE OXYGEN METABOLITE; UNINDEXED DRUG; VANILLOID RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VESICULAR GLUTAMATE TRANSPORTER 1; VIMENTIN; BIOLOGICAL MARKER; CANNABINOID; CANNABINOID RECEPTOR;

ALZHEIMER DISEASE; ASTROCYTE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; EPILEPSY; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOREACTIVITY; LIPID PEROXIDATION; MENTAL DISEASE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; REVIEW; SCHIZOPHRENIA; SCIATIC NERVE INJURY; ANIMAL; CELL COMMUNICATION; DEGENERATIVE DISEASE; DRUG EFFECTS; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; PHYSIOLOGY;

ANIMALS; ASTROCYTES; BIOMARKERS; CANNABIDIOL; CANNABINOIDS; CELL COMMUNICATION; EPILEPSY; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; NEUROGENESIS; RECEPTORS, CANNABINOID;

EID: 85026728612     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18081669     Document Type: Review

References (131)

1. Pereira, A., Furlan, F.A. Astrocytes and human cognition: Modeling information integration and modulation of neuronal activity. Prog. Neurobiol. 2010, 92, 405-420, doi:10.1016/j.pneurobio.2010.07.001.
2. Jensen, C.J., Massie, A., De Keyser, J. Immune players in the CNS: The astrocyte. J. Neuroimmune Pharmacol. 2013, 8, 824-839, doi:10.1007/s11481-013-9480-6.
3. Sofroniew, M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32, 638-647, doi:10.1016/j.tins.2009.08.002.
4. Sofroniew, M.V., Vinters, H.V. Astrocytes: Biology and pathology. Acta Neuropathol. 2010, 119, 7-35, doi:10.1007/s00401-009-0619-8.
5. Ridet, J.L., Malhotra, S.K., Privat, A., Gage, F.H. Reactive astrocytes: Cellular and molecular cues to biological function. Trends Neurosci. 1997, 20, 570-577.
6. Ransohoff, R.M. How neuroinflammation contributes to neurodegeneration. Science 2016, 353, 777-783, doi:10.1126/science.aag2590.
7. Walter, L., Stella, N. Cannabinoids and neuroinflammation. Br. J. Pharmacol. 2004, 141, 775-785.
8. Stella, N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58, 1017-1030.
9. Navarrete, M., Díez, A., Araque, A. Astrocytes in endocannabinoid signalling. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369, 20130599, doi:10.1098/rstb.2013.0599.
10. Vázquez, C., Tolón, R.M., Pazos, M.R., Moreno, M., Koester, E.C., Cravatt, B.F., Hillard, C.J., Romero, J. Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. Neurobiol. Dis. 2015, 79, 41-50, doi:10.1016/j.nbd.2015.04.005.
11. Benito, C., Kim, W.K., Chavarría, I., Hillard, C.J., Mackie, K., Tolón, R.M., Williams, K., Romero, J. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J. Neurosci. 2005, 25, 2530-2536.
12. Cassano, T., Calcagnini, S., Pace, L., De Marco, F., Romano, A., Gaetani, S. Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. Front. Neurosci. 2017, 11, 30, doi:10.3389/fnins.2017.00030.
13. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., Shohami, E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413, 527-531.
14. Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M., Mechoulam, R. Endocannabinoids and traumatic brain injury. Br. J. Pharmacol. 2011, 163, 1402-1410, doi:10.1111/j.1476-5381.2011.01343.x.
15. Gómez Del Pulgar, T., De Ceballos, M.L., Guzmán, M., Velasco, G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 2002, 277, 36527-36533.
16. Molina-Holgado, E., Vela, J.M., Arévalo-Martín, A., Almazán, G., Molina-Holgado, F., Borrell, J., Guaza, C. Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 2002, 22, 9742-9753.
17. Lubman, D.I., Cheetham, A., Yücel, M. Cannabis and adolescent brain development. Pharmacol. Ther. 2015, 148, 1-16, doi:10.1016/j.pharmthera.2014.11.009.
18. Callén, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortés, A., Mallol, J., Casadó, V., Lanciego, J.L., Franco, R., Lluis, C., et al. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J. Biol. Chem. 2012, 287, 20851-20865, doi:10.1074/jbc.M111.335273.
19. Zuardi, A.W. Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 2008, 30, 271-280.
20. Izzo, A.A., Borrelli, F., Capasso, R., Di Marzo, V., Mechoulam, R. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 2009, 30, 515-527, doi:10.1016/j.tips.2009.07.006.
21. Hayakawa, K., Mishima, K., Fujiwara, M. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals 2010, 3, 2197-2212.
22. Fernández-Ruiz, J., Sagredo, O., Pazos, M.R., García, C., Pertwee, R., Mechoulam, R., Martínez-Orgado, J. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 2013, 75, 323-333, doi:10.1111/j.1365-2125.2012.04341.x.
23. Burstein, S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg. Med. Chem. 2015, 23, 1377-1385, doi:10.1016/j.bmc.2015.01.059.
24. Campos, A.C., Fogaça, M.V., Sonego, A.B., Guimarães, F.S. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 2016, 112, 119-127, doi:10.1016/j.phrs.2016.01.033.
25. Hampson, A.J., Grimaldi, M., Axelrod, J., Wink, D. Cannabidiol and (−)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 1998, 95, 8268-8273.
26. Castillo, A., Tolón, M.R., Fernández-Ruiz, J., Romero, J., Martinez-Orgado, J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol. Dis. 2010, 37, 434-440, doi:10.1016/j.nbd.2009.10.023.
27. Pazos, M.R., Cinquina V., Gómez, A., Layunta, R., Santos, M., Fernández-Ruiz, J., Martínez-Orgado, J. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 2012, 63, 776-783, doi:10.1016/j.neuropharm.2012.05.034
28. Alvarez, F.J., Lafuente, H., Rey-Santano, M.C., Mielgo, V.E., Gastiasoro, E., Rueda, M., Pertwee, R.G., Castillo, A.I., Romero, J., Martínez-Orgado, J. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr. Res. 2008, 64, 653-658, doi:10.1203/PDR.0b013e318186e5dd.
29. Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., Vogel, Z. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem. 2010, 285, 1616-1626, doi:10.1074/jbc.M109.069294.
30. Juknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Gao, F., Coppola, G., Geschwind, D., Vogel, Z. Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PLoS ONE 2013, 8, e61462, doi:10.1371/journal.pone.0061462.
31. DiSabato, D.J., Quan, N., Godbout, J.P. Neuroinflammation: The devil is in the details. J. Neurochem. 2016, 139, 136-153, doi:10.1111/jnc.13607.
32. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., Izzo, A.A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 2004, 89, 134-141.
33. Juknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Coppola, G., Geschwind, D., Vogel, Z. Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Br. J. Pharmacol. 2012, 165, 2512-2528, doi:10.1111/j.1476-5381.2011.01461.x.
34. Lo, E.H., Dalkara, T., Moskowitz, M.A. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 2003, 4, 399-415.
35. Robel, S., Berninger, B., Götz, M. The stem cell potential of glia: Lessons from reactive gliosis. Nat. Rev. Neurosci. 2011, 12, 88-104, doi:10.1038/nrn2978.
36. Kindy, M.S., Bhat, A.N., Bhat, N.R. Transient ischemia stimulates glial fibrillary acid protein and vimentin gene expression in the gerbil neocortex, striatum and hippocampus. Brain Res. Mol. Brain Res. 1992, 13, 199-206.
37. Cheung, W.M., Wang, C.K., Kuo, J.S., Lin, T.N. Changes in the level of glial fibrillary acidic protein (GFAP) after mild and severe focal cerebral ischemia. Chin. J. Physiol. 1999, 42, 227-235.
38. Petito, C.K., Halaby, I.A. Relationship between ischemia and ischemic neuronal necrosis to astrocyte expression of glial fibrillary acidic protein. Int. J. Dev. Neurosci. 1993, 11, 239-247.
39. Stoll, G., Jander, S., Schroeter, M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol. 1998, 56, 149-171.
40. England, T.J., Hind, W.H., Rasid, N.A., O’Sullivan, S.E. Cannabinoids in experimental stroke: A systematic review and meta-analysis. J. Cereb. Blood Flow Metab. 2015, 35, 348-358, doi:10.1038/jcbfm.2014.218.
41. Hayakawa, K., Mishima, K., Irie, K., Hazekawa, M., Mishima, S., Fujioka, M., Orito, K., Egashira, N., Katsurabayashi, S., Takasaki, K., et al. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 2008, 55, 1280-1286, doi:10.1016/j.neuropharm.2008.06.040.
42. Schiavon, A.P., Soares, L.M., Bonato, J.M., Milani, H., Guimarães, F.S., Weffort de Oliveira, R.M. Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox. Res. 2014, 26, 307-316, doi:10.1007/s12640-014-9457-0.
43. Mohammed, N., Ceprian, M., Jimenez, L., Pazos, M.R., Martínez-Orgado, J. Neuroprotective Effects of Cannabidiol in Hypoxic Ischemic Insult. The Therapeutic Window in Newborn Mice. CNS Neurol. Disord. Drug Targets 2017, 16,102-108, doi:10.2174/1871527315666160927110305.
44. Ceprián, M., Jiménez-Sánchez, L., Vargas, C., Barata, L., Hind, W., Martínez-Orgado, J. Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Neuropharmacology 2017, 116, 151-159, doi:10.1016/j.neuropharm.2016.12.017.
45. Lafuente, H., Alvarez, F.J., Pazos, M.R., Alvarez, A., Rey-Santano, M.C., Mielgo, V., Murgia-Esteve, X., Hilario, E., Martinez-Orgado, J. Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs. Pediatr. Res. 2011, 70, 272-277, doi:10.1203/PDR.0b013e3182276b11.
46. Li, C., Zhao, R., Gao, K., Wei, Z., Yin, M.Y., Lau, L.T., Chui, D., Yu, A.C. Astrocytes: Implications for neuroinflammatory pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res. 2011, 8, 67-80.
47. Hind, W.H., England, T.J., O’Sullivan, S.E. Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors. Br. J. Pharmacol. 2016, 173, 815-825, doi:10.1111/bph.13368.
48. Pekny, M., Nilsson, M. Astrocyte activation and reactive gliosis. Glia 2005, 50, 427-434.
49. Pekny, M., Pekna, M. Astrocyte intermediate filaments in CNS pathologies and regeneration. J. Pathol. 2004, 204, 428-437.
50. Perez, M., Benitez, S.U., Cartarozzi, L.P., Del Bel, E., Guimarães, F.S., Oliveira, A.L. Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats. Eur. J. Neurosci. 2013, 38, 3424-3434, doi:10.1111/ejn.12341.
51. Rao, V.L.R., Rao, A.M., Dogan, A., Bowen, K.K., Hatcher, J., Rothstein, J.D., Dempsey, R.J. Glial glutamate transporter GLT-1 down-regulation precedes delayed neuronal death in gerbil hippocampus following transient global cerebral ischemia. Neurochem. Int. 2000, 36, 531-537.
52. Koo, E.H., Lansbury, P.T., Kelly, J.W. Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. USA 1999, 96, 9989-9990.
53. Singh, A., Abraham, W.C. Astrocytes and synaptic plasticity in health and disease. Exp. Brain Res. 2017, 235, 1645-1655, doi:10.1007/s00221-017-4928-1.
54. Larsson, A., Wilhelmsson, U., Pekna, M., Pekny, M. Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP(−/−)Vim(−/−) mice. Neurochem. Res. 2004, 29, 2069-2073.
55. Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A.A., Iuvone, T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J. Mol. Med. 2006, 84, 253-358.
56. Karl, T., Garner, B., Cheng, D. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease. Behav. Pharmacol. 2017, 28, 142-160, doi:10.1097/FBP.0000000000000247.
57. Esposito, G., Scuderi, C., Savani, C., Steardo, L., Jr., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V., Steardo, L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 2007, 151, 1272-1279.
58. Esposito, G., Scuderi, C., Valenza, M., Togna, G.I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M.R., Iuvone, T., Steardo, L. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS ONE 2011, 6, e28668, doi:10.1371/journal.pone.0028668.
59. Trapp, B.D., Nave, K.A. Multiple sclerosis: An immune or neurodegenerative disorder? Annu. Rev. Neurosci. 2008, 31, 247-269, doi:10.1146/annurev.neuro.30.051606.094313.
60. Izikson, L., Klein, R.S., Charo, I.F., Weiner, H.L., Luster, A.D. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 2000, 192, 1075-1080.
61. Mayo, L., Trauger, S.A., Blain, M., Nadeau, M., Patel, B., Alvarez, J.I., Mascanfroni, I.D., Yeste, A., Kivisäkk, P., Kallas, K., et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat. Med. 2014, 20, 1147-1156, doi:10.1038/nm.3681.
62. Ludwin, S.K., Rao, V.T., Moore, C.S., Antel, J.P. Astrocytes in multiple sclerosis. Mult. Scler. 2016, 22, 1114-1124, doi:10.1177/1352458516643396.
63. Eng, L.F., Vanderhaeghen, J.J., Bignami, A., Gerstl, B. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971, 28, 351-354.
64. Mayo, L., Quintana, F.J., Weiner, H.L. The innate immune system in demyelinating disease. Immunol. Rev. 2012, 248, 170-187, doi:10.1111/j.1600-065X.2012.01135.x.
65. Farez, M.F., Correale, J. Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis. J. Neurol. Sci. 2016, 361, 360-365, doi:10.1016/j.jns.2015.12.022.
66. Lyman, W.D., Sonett, J.R., Brosnan, C.F., Elkin, R., Bornstein, M.B. Delta 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1989, 23, 73-81.
67. Pryce, G., Ahmed, Z., Hankey, D.J., Jackson, S.J., Croxford, J.L., Pocock, J.M., Ledent, C., Petzold, A., Thompson, A.J., Giovannoni, G., et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126, 2191-2202.
68. Maresz, K., Pryce, G., Ponomarev, E.D., Marsicano, G., Croxford, J.L., Shriver, L.P., Ledent, C., Cheng, X., Carrier, E.J., Mann, M.K., et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 2007, 13, 492-497.
69. De Lago, E., Moreno-Martet, M., Cabranes, A., Ramos, J.A., Fernández-Ruiz, J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 2012, 62, 2299-2308, doi:10.1016/j.neuropharm.2012.01.030.
70. Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A., Vogel, Z. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br. J. Pharmacol. 2011, 163, 1507-1519, doi:10.1111/j.1476-5381.2011.01379.x.
71. Kozela, E., Juknat, A., Kaushansky, N., Rimmerman, N., Ben-Nun, A., Vogel, Z. Cannabinoids decrease the th17 inflammatory autoimmune phenotype. J. Neuroimmune Pharmacol. 2013, 8, 1265-1276, doi:10.1007/s11481-013-9493-1.
72. Kozela, E., Juknat, A., Kaushansky, N., Ben-Nun, A., Coppola, G., Vogel, Z. Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells. J. Neuroinflamm. 2015, 12, 52, doi:10.1186/s12974-015-0273-0.
73. Kozela, E., Juknat, A., Gao, F., Kaushansky, N., Coppola, G., Vogel, Z. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. J. Neuroinflamm. 2016, 13, 136, doi:10.1186/s12974-016-0603-x.
74. Mecha, M., Feliú, A., Iñigo, P.M., Mestre, L., Carrillo-Salinas, F.J., Guaza, C. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiol. Dis. 2013, 59, 141-150, doi:10.1016/j.nbd.2013.06.016.
75. Feliú, A., Moreno-Martet, M., Mecha, M., Carrillo-Salinas, F.J., de Lago, E., Fernández-Ruiz, J., Guaza, C. A Sativex(®)-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Br. J. Pharmacol. 2015, 172, 3579-3595, doi:10.1111/bph.13159.
76. Sobel, R.A., Ahmed, A.S. White matter extracellular matrix chondroitin sulfate/dermatan sulfate proteoglycans in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2001, 60, 1198-1207.
77. Haylock-Jacobs, S., Keough, M.B., Lau, L., Yong, V.W. Chondroitin sulphate proteoglycans: Extracellular matrix proteins that regulate immunity of the central nervous system. Autoimmun. Rev. 2011, 10, 766-772, doi:10.1016/j.autrev.2011.05.019.
78. Giacoppo, S., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., Mazzon, E. A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis. Daru 2015, 23, 48, doi:10.1186/s40199-015-0131-8.
79. Roze, E., Bonnet, C., Betuing, S., Caboche, J. Huntington’s disease. Adv. Exp. Med. Biol. 2010, 685, 45-63.
80. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., Schram, K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav. 1991, 40, 701-708.
81. Valdeolivas, S., Satta, V., Pertwee, R.G., Fernández-Ruiz, J., Sagredo, O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: Role of CB1 and CB2 receptors. ACS Chem. Neurosci. 2012, 3, 400-406, doi:10.1021/cn200114w.
82. Bak, L.K., Schousboe, A., Waagepetersen, H.S. The glutamate/GABA-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 2006, 98, 641-653.
83. Kardos, J., Héja, L., Jemnitz, K., Kovács, R., Palkovits, M. The nature of early astroglial protection—Fast activation and signaling. Prog. Neurobiol. 2017, 153, 86-99, doi:10.1016/j.pneurobio.2017.03.005.
84. Stringer, J.L. Repeated seizures increase GFAP and vimentin in the hippocampus. Brain Res. 1996, 717, 147-153.
85. Russo, E.B. Cannabis and epilepsy: An ancient treatment returns to the fore. Epilepsy Behav. 2017, 70, 292-297, doi:10.1016/j.yebeh.2016.09.040
86. Mechoulam, R., Carlini, E.A. Toward drugs derived from cannabis. Naturwissenschaften 1978, 65, 174-179.
87. Karler, R., Cely, W., Turkanis, S.A. The anticonvulsant activity of cannabidiol and cannabinol. Life Sci. 1973, 13, 1527-1531.
88. Chiu, P., Olsen, D.M., Borys, H.K., Karler, R., Turkanis, S.A. The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 1979, 20, 365-375.
89. Karler, R., Turkanis, SA. The cannabinoids as potential antiepileptics. J. Clin. Pharmacol. 1981, 21, 437S-448S.
90. Mao, K., You, C., Lei, D., Zhang H. High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect. Int. J. Clin. Exp. Med. 2015, 8, 8820-8827.
91. Wang, Q., Jie, W., Liu J.H., Yang, J.M., Gao, T.M. An astroglial basis of major depressive disorder? An overview. Glia 2017, 65, 1227-1250, doi:10.1002/glia.23143.
92. Bender, C.L., Calfa, G.D., Molina, V.A. Astrocyte plasticity induced by emotional stress: A new partner in psychiatric physiopathology? Prog. Neuropsychopharmacol. Biol. Psychiatry 2016, 65, 68-77, doi:10.1016/j.pnpbp.2015.08.005.
93. Guimarães, F.S., Chiaretti, T.M., Graeff, F.G., Zuardi, A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 1990, 100, 558-559.
94. Casarotto, P.C., Gomes, F.V., Resstel, L.B., Guimarães, F.S. Cannabidiol inhibitory effect on marble-burying behaviour: Involvement of CB1 receptors. Behav. Pharmacol. 2010, 21, 353-358.
95. Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A.E., et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011, 36, 1219-1226, doi:10.1038/npp.2011.6.
96. Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkötter J., Hellmich M., Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2012, 2, e94, doi:10.1038/tp.2012.15.
97. Khoury, J.M., Neves, M.C.L.D., Roque, M.A.V., Queiroz, D.A.B., Corrêa de Freitas, A.A., de Fátima, Â., Moreira, F.A., Garcia, F.D. Is there a role for cannabidiol in psychiatry? World J. Biol. Psychiatry 2017, 20, 1-16, doi:10.1080/15622975.2017.1285049.
98. Gomes, F.V., Llorente, R., Del Bel, E.A., Viveros, M.P., López-Gallardo, M., Guimarães, F.S. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr. Res. 2015, 164, 155-163, doi:10.1016/j.schres.2015.01.015.
99. Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C.V., Hurd, Y.L. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J. Neurosci. 2009, 29, 14764-14769, doi:10.1523/JNEUROSCI.4291-09.2009.
100. Hurd, Y.L., Yoon, M., Manini, A.F., Hernandez, S., Olmedo, R., Ostman, M., Jutras-Aswad, D. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics 2015, 12, 807-815, doi:10.1007/s13311-015-0373-7.
101. Lacagnina, M.J., Rivera, P.D., Bilbo, S.D. Glial and Neuroimmune Mechanisms as Critical Modulators of Drug Use and Abuse. Neuropsychopharmacology 2017, 42, 156-177, doi:10.1038/npp.2016.121.
102. Snyder, J.S., Cameron, H.A. Could adult hippocampal neurogenesis be relevant for human behavior? Behav. Brain Res. 2012, 227, 384-390, doi:10.1016/j.bbr.2011.06.024
103. Mendez-David, I., Hen, R., Gardier, A.M., David, D.J. Adult hippocampal neurogenesis: An actor in the antidepressant-like action. Ann. Pharm. Fr. 2013, 71, 143-149, doi:10.1016/j.pharma.2013.02.006.
104. Colangelo, A.M., Cirillo, G., Lavitrano, M.L., Alberghina, L., Papa M. Targeting reactive astrogliosis by novel biotechnological strategies. Biotechnol. Adv. 2012, 30, 261-271, doi:10.1016/j.biotechadv.2011.06.016.
105. Saha, B., Jaber, M., Gaillard, A. Potentials of endogenous neural stem cells in cortical repair. Front. Cell. Neurosci. 2012, 6, 14, doi:10.3389/fncel.2012.00014. eCollection 2012.
106. Revest, J.M., Dupret, D., Koehl, M., Funk-Reiter, C., Grosjean, N., Piazza, P.V., Abrous, D.N. Adult hippocampal neurogenesis is involved in anxiety-related behaviors. Mol. Psychiatry 2009, 14, 959-967, doi:10.1038/mp.2009.15.
107. Campos, A.C., Ortega, Z., Palazuelos, J., Fogaça, M.V., Aguiar, D.C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F.A., Guzmán, M., et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system. Int. J. Neuropsychopharmacol. 2013, 16, 1407-1419, doi:10.1017/S1461145712001502.
108. Shinjyo, N., Di Marzo, V. The effect of cannabichromene on adult neural stem/progenitor cells. Neurochem. Int. 2013, 63, 432-437, doi:10.1016/j.neuint.2013.08.002.
109. Sagan, S., Venance, L., Torrens, Y., Cordier, J., Glowinski, J., Giaume, C. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. J. Neurosci. 1999, 11, 691-699.
110. Walter, L., Stella, N. Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes. Glia 2003, 44, 85-90.
111. Zurolo, E., Iyer, A.M., Spliet, W.G., Van Rijen, P.C., Troost, D., Gorter, J.A., Aronica, E. CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies. Neuroscience 2010, 170, 28-41, doi:10.1016/j.neuroscience.2010.07.004.
112. Sheng, W.S., Hu, S., Min, X., Cabral, G.A., Lokensgard, J.R., Peterson, P.K. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 2005, 49, 211-219.
113. Metna-Laurent, M., Marsicano, G. Rising stars: Modulation of brain functions by astroglial type-1 cannabinoid receptors. Glia 2015, 63, 353-364, doi:10.1002/glia.22773.
114. Oliveira da Cruz, J.F., Robin, L.M., Drago, F., Marsicano, G., Metna-Laurent, M. Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse. Neuroscience 2016, 323, 35-42, doi:10.1016/j.neuroscience.2015.05.002.
115. Chen, Y., Buck, J. Cannabinoids protect cells from oxidative cell death: A receptor-independent mechanism. J. Pharmacol. Exp. Ther. 2000, 293, 807-812.
116. Rimmerman, N., Kozela, E., Levy, R., Vogel, Z., Juknat, A. Cannabinoid Signaling Through Non-CB1R/Non-CB2R Targets in Microglia. In endoCANNABINOIDS, Abood, M., Sorensen, R., Stella, N., Eds., Springer: New York, NY, USA, 2013, Volume 24, pp. 143-171.
117. Rimmerman, N., Juknat, A., Kozela, E., Levy, R., Bradshaw, H.B., Vogel, Z. The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells. Cell. Mol. Neurobiol. 2011, 31, 921-930, doi:10.1007/s10571-011-9692-3.
118. Campos, A.C., Moreira, F.A., Gomes, F.V., Del Bel, E.A., Guimarães, F.S. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2012, 367, 3364-3378, doi:10.1098/rstb.2011.0389.
119. Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M.P., Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J. Pharmacol. Exp. Ther. 2004, 308, 838-845.
120. Marcu, J.P., Christian, R.T., Lau, D., Zielinski, A.J., Horowitz, M.P., Lee, J., Pakdel, A., Allison, J., Limbad, C., Moore, D.H., et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol. Cancer Ther. 2010, 9, 180-189, doi:10.1158/1535-7163.MCT-09-0407.
121. Nabissi, M., Morelli, M.B., Santoni, M., Santoni, G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 2013, 34, 48-57, doi:10.1093/carcin/bgs328.
122. Carracedo, A., Geelen, M.J., Diez, M., Hanada, K., Guzmán, M., Velasco, G. Ceramide sensitizes astrocytes to oxidative stress: Protective role of cannabinoids. Biochem. J. 2004, 380, 435-440.
123. Rimmerman, N., Ben-Hail, D., Porat, Z., Juknat, A., Kozela, E., Daniels, M.P., Connelly, P.S., Leishman, E., Bradshaw, H.B., Shoshan-Barmatz, V., et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: A novel mechanism for cannabinoid-induced cell death. Cell Death Dis. 2013, 4, e949, doi:10.1038/cddis.2013.471.
124. Meares, G.P., Ma, X., Qin, H., Benveniste, E.N. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 2012, 60, 771-781, doi:10.1002/glia.22307.
125. Middeldorp, J., Hol, E.M. GFAP in health and disease. Prog. Neurobiol. 2011, 93, 421-443, doi:10.1016/j.pneurobio.2011.01.005.
126. Matyash, V., Kettenmann, H. Heterogeneity in astrocyte morphology and physiology. Brain Res. Rev. 2010, 63, 2-10, doi:10.1016/j.brainresrev.2009.12.001.
127. Zamanian, J.L., Xu, L., Foo, L.C., Nouri, N., Zhou, L., Giffard, R.G., Barres, B.A. Genomic analysis of reactive astrogliosis. J. Neurosci. 2012, 32, 6391-6410, doi:10.1523/JNEUROSCI.6221-11.2012.
128. Liddelow, S.A., Guttenplan, K.A., Clarke, L.E., Bennett, F.C., Bohlen, C.J., Schirmer, L., Bennett, M.L., Münch, A.E., Chung, W.S., Peterson, T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017, 541, 481-487, doi:10.1038/nature21029.
129. Ransohoff, R.M. A polarizing question: Do M1 and M2 microglia exist? Nat. Neurosci. 2016, 19, 987-991, doi:10.1038/nn.4338.
130. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., Gallily, R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006, 39, 143-151.
131. Hegde, V.L., Singh, U.P., Nagarkatti, P.S., Nagarkatti, M. Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo. J. Immunol. 2015, 194, 5211-5222, doi:10.4049/jimmunol.1401844.